unexpect
diseas
sever
acut
respiratori
syndrom
sar
avian
influenza
becom
seriou
threat
public
health
immedi
respons
imper
take
consider
exist
licens
antivir
drug
viral
diseas
alreadi
known
safe
use
human
report
evid
present
proteas
inhibitor
pi
current
use
therapi
might
exert
effect
sar
perhap
avian
influenza
evid
potenti
benefit
pi
sar
coronaviru
sarscov
provid
empir
clinic
studi
vivo
viral
inhibit
assay
comput
simul
dock
compound
activ
site
main
sarscov
proteas
suggest
silico
dock
molecul
theoret
model
subunit
type
influenza
viru
rnadepend
rna
polymeras
also
exist
remot
possibl
pi
may
effect
avian
influenza
virus
although
evid
still
far
definit
result
far
obtain
suggest
pi
serious
taken
consider
test
potenti
therapeut
agent
sar
avian
influenza
epidem
newli
describ
sever
acut
respiratori
syndrom
sar
confront
world
lifethreaten
diseas
definit
treatment
protocol
exist
unexpect
diseas
becom
seriou
threat
public
health
immedi
action
taken
time
specif
drug
design
safeti
test
therefor
antivir
drug
alreadi
licens
viral
diseas
known
safe
human
taken
consider
part
immedi
respons
regard
exampl
sar
reveal
apart
palli
treatment
corticosteroid
promis
antisar
coronaviru
sarscov
molecul
date
recycl
drug
known
effect
viral
diseas
includ
interferon
ribavirin
chloroquin
proteas
inhibitor
pi
first
broad
spectrum
tel
mobil
fax
email
address
asavarino
medscapecom
antivir
drug
induc
degrad
viral
rna
ribavirin
often
use
combin
interferon
stroher
et
al
exert
antivir
activ
directli
lethal
mutagenesi
viral
genet
materi
crotti
et
al
report
studi
inhibit
sarscov
replic
chu
et
al
stroher
et
al
chloroquin
first
choic
antimalari
malaria
parasit
plasmodium
falciparum
develop
widespread
resist
later
drug
found
applic
rheumat
diseas
shown
exert
effect
like
due
inhibit
glycosyl
viral
envelop
glycoprotein
review
effect
chloroquin
publish
februari
issu
journal
savarino
et
al
savarino
et
al
chloroquin
capac
interfer
viral
particl
matur
open
potenti
applic
diseas
caus
envelop
virus
follow
suggest
chloroquin
might
effect
sarscov
savarino
et
al
keyaert
et
al
show
drug
effect
inhibitor
sarscov
replic
vitro
pi
effect
treatment
effect
viral
diseas
central
topic
paper
first
review
known
effect
drug
sar
discuss
ground
consid
drug
context
avian
influenza
activ
pi
base
inhibit
aspart
proteas
respons
cleavag
gagpol
polypeptid
contain
main
viral
enzym
structur
viral
core
protein
inhibit
proteas
lead
product
immatur
viral
particl
inhibit
viral
replic
although
pi
design
effect
inhibitor
replic
show
inhibitori
effect
wide
spectrum
pathogen
inde
inhibitori
effect
pi
shown
candida
albican
casson
et
al
recent
p
falciparum
savarino
et
al
activ
seem
due
inhibit
nonretrovir
aspart
proteas
c
albican
secretori
aspart
proteas
sap
p
falciparum
plasmepsin
threedimension
architectur
microbi
proteas
resembl
proteas
tacconelli
et
al
savarino
et
al
press
drug
kaletra
combin
pi
ritonavir
lopinavir
found
benefit
individu
sar
rather
surpris
sarscov
genom
encod
aspart
proteas
despit
lack
doubleblind
placebocontrol
clinic
trial
clinic
experi
physician
involv
care
peopl
sar
great
epidem
strongli
suggest
lopinavirritonavir
taken
consider
clinic
manag
diseas
retrospect
match
cohort
studi
chan
et
al
found
addit
lopinavirritonavir
standard
initi
treatment
protocol
associ
reduct
overal
death
rate
intub
rate
compar
match
cohort
receiv
standard
treatment
respect
p
lower
necess
methylprednisolon
high
dose
anoth
studi
chu
et
al
evalu
effect
kaletra
associ
ribavirin
advers
clinic
outcom
acut
respiratori
distress
syndrom
death
significantli
lower
treatment
group
histor
control
treat
ribavirin
alon
versu
p
day
onset
symptom
studi
conclud
randomis
trial
would
need
valid
result
possibl
use
lopinavirritonavir
sar
treatment
option
sar
return
consider
potenti
antisar
benefit
substanc
made
interest
paper
chen
cao
author
observ
none
peopl
hospitalis
togeth
individu
sar
hospit
floor
contract
sar
chen
cao
howev
subject
antiretrovir
regimen
receiv
proteas
inhibitor
indinavir
remain
differ
combin
revers
transcriptas
inhibitor
attribut
observ
casualti
difficult
accord
report
chen
cao
individu
inde
close
contact
sar
medic
worker
serv
floor
contract
sar
possibl
effect
due
viral
interfer
andor
nonspecif
antivir
factor
induc
howev
report
chen
cao
also
rais
hypothesi
antisar
effect
might
unexpect
properti
antiretrovir
drug
gener
properti
pi
clinic
effect
antiretrovir
drug
sar
initi
attribut
nonspecif
antiinflammatori
effect
later
vitro
studi
show
member
pi
class
could
inde
exert
direct
antivir
effect
sarscov
yamamoto
et
al
show
proteas
inhibitor
nelfinavir
ritonavir
significantli
effici
inhibit
viral
antigen
express
measur
immunofluoresc
product
virion
measur
realtim
rtpcr
cytopath
effect
measur
methyl
tetrazolium
assay
vero
cell
infect
sarscov
multipl
infect
moreov
timeofaddit
experi
show
nelfinavir
inhibit
sarscov
replic
postentri
step
yamamoto
et
al
chu
et
al
show
lopinavir
inhibit
cytopath
effect
sarscov
measur
plaquereduct
assay
foetal
rhesu
cell
note
effect
lopinavir
synergist
ribavirin
therefor
chu
cowork
attribut
antivir
synerg
clinic
benefit
observ
individu
sar
treat
ribavirin
plu
kaletra
screen
effect
differ
antivir
compound
clinic
isol
sarscov
compound
includ
nucleosid
revers
transcriptas
inhibitor
nrti
zidovudin
stavudin
nonnucleosid
revers
transcriptas
inhibitor
nnrti
nevirapin
pi
ritonavir
lopinavir
lopinavir
result
exert
detect
effect
sarscov
ec
lopinavir
rang
h
postinfect
h
postinfect
cell
line
howev
warn
antivir
effect
variabl
cell
line
depend
exampl
ec
lopinavir
prototyp
sarscov
strain
rang
cell
vero
cell
therefor
like
antivir
effect
antisar
compound
report
literatur
exagger
underestim
depend
assay
cell
line
use
differ
group
regard
exampl
ribavirin
interest
report
inhibitor
sarscov
replic
other
report
exert
antivir
effect
concentr
high
reach
vivo
chu
et
al
stroher
et
al
member
coronavirida
famili
sarscov
encod
three
differ
proteas
one
proteas
pro
main
coronaviru
proteas
sun
et
al
yang
et
al
like
target
pi
jenwitheesuk
samudrala
b
preliminari
data
yamamoto
et
al
indic
pro
inhibit
though
partial
lopinavir
deriv
ritonavir
appar
surpris
pro
cystein
proteas
rather
aspart
proteas
activ
site
sarscov
pro
cy
form
catalyt
dyad
anand
et
al
cystein
proteas
usual
display
catalyt
triad
consist
serin
histidin
aspart
howev
structur
sarscov
pro
show
aspart
residu
vicin
cy
sarscov
pro
homodim
monom
compris
three
domain
anand
et
al
first
two
domain
show
chymotrypsinlik
fold
root
mean
squar
deviat
bovin
p
fig
respons
catalyt
reaction
third
domain
play
critic
role
enzym
dimeris
shi
et
al
chymotrypsinlik
fold
pro
intrigu
overal
sequenc
ident
two
protein
quit
low
chymotrypsin
protein
similar
fold
serin
proteas
rais
hypothesi
pro
origin
chymotrypsinlik
serin
proteas
later
evolv
cystein
proteas
et
al
chymotrypsinfold
proteas
may
target
pi
support
vitro
experi
independ
group
show
pi
also
inhibit
chymotrypsinlik
compon
mammalian
proteasom
piccinini
et
al
schmidtk
et
al
limit
experiment
evid
avail
inhibitori
effect
pi
pro
support
comput
simul
reveal
catalyt
site
pro
allow
dock
sever
pi
silico
simul
adopt
ie
genet
algorithm
gold
use
ligandprotein
dock
techniqu
use
success
predict
suscept
p
falciparum
pi
savarino
et
al
savarino
et
al
shown
fig
clinic
use
pi
partial
fill
bind
caviti
pro
gold
fit
score
obtain
ritonavir
saquinavir
indinavir
indic
stabl
ligandprotein
interact
ritonavir
howev
found
display
signific
hydrogen
bond
pro
data
shown
observ
line
previou
calcul
independ
group
use
pro
sarscov
transmiss
gastroenter
viru
tgev
jenwitheesuk
samudrala
zhang
yap
among
variou
compound
test
zhang
yap
indic
ritonavir
compound
highest
bind
affin
k
author
attribut
kaletra
compon
lopinavir
k
zhang
yap
instead
jenwitheesuk
samudrala
attribut
ritonavir
k
calcul
attribut
ritonavir
k
reason
discrep
due
differ
method
adopt
abovement
author
use
differ
molecular
dynam
md
techniqu
calcul
bind
affin
instead
estim
theoret
bind
affin
pi
pro
base
correl
dock
fit
experiment
data
embed
gold
program
dataset
compar
gold
fit
score
obtain
panel
potenti
inhibitor
experiment
determin
k
may
argu
sarscov
pro
protein
chymotrypsin
fold
event
k
estim
realist
previous
report
given
pi
determin
inhibit
proteas
partial
yamamoto
et
al
although
experi
provid
causal
link
pro
inhibit
impair
sarscov
replic
still
lack
pro
indic
group
main
target
pi
sarscov
virolog
biochem
bioinformat
data
seem
agre
regard
fact
experiment
lopinavir
ritonavir
partial
inhibit
pro
exclud
possibl
causal
link
pro
sarscov
inhibit
inde
extent
pro
inhibit
necessari
exert
antivir
effect
still
known
howev
exclud
inhibit
postentri
step
viral
life
cycl
may
contribut
antisarscov
effect
pi
possibl
pi
may
dock
activ
site
pro
intrigu
extend
potenti
effect
drug
beyond
organ
possess
aspart
proteas
resembl
proteas
anoth
target
pi
might
put
proteas
compon
rnadirect
rna
polymeras
rdrp
type
influenza
viru
orthomyxovirida
long
believ
encod
proteas
observ
hara
et
al
b
suggest
chymotrypsinlik
proteas
might
hidden
carboxytermin
region
pa
subunit
rdrp
hara
et
al
b
conclus
base
observ
capac
pa
cleav
chymotrypsinspecif
substrat
amidolyt
activ
peculiar
featur
chymotrypsin
hara
et
al
hara
et
al
show
mutat
analysi
pa
could
serin
proteas
ser
activ
site
abolit
put
chymotrypsinlik
proteas
activ
pa
substitut
catalyt
ser
residu
ala
significantli
decreas
yield
viral
progeni
toyoda
et
al
hara
et
al
identifi
activ
residu
catalyt
triad
asp
level
conserv
pa
type
influenza
virus
howev
survey
public
sequenc
databas
shown
asp
conserv
pa
influenza
virus
theoret
observ
contradict
fig
dock
proteas
inhibitor
pi
saquinavir
activ
site
sever
acut
respiratori
syndrom
coronaviru
sarscov
main
proteas
molecular
surfac
correspond
catalyt
cy
residu
shown
blue
red
respect
molecular
dock
comput
use
genet
algorithm
gold
cambridg
crystallograph
data
centr
cambridg
uk
visualis
use
program
swisspdbview
avail
wwwexpasyorg
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
theori
hara
et
al
chymotrypsinlik
proteas
function
activ
proteas
without
aspart
residu
one
exampl
abovedescrib
catalyt
dyad
pro
altern
lewi
base
vicin
might
replac
asp
residu
third
compon
triad
line
observ
hara
et
al
carboxytermin
region
pa
believ
respons
chymotrypsinlik
activ
analysi
show
signific
though
moder
similar
ident
accord
clustalw
calcul
http
npsapbilibcpfrcgibinnpsa
automatpl
pagenpsa
clustalwhtml
ser
might
correspond
ser
chymotrypsin
hara
et
al
accord
calcul
second
similar
protein
carboxytermin
region
pa
among
protein
analys
sarscov
pro
shown
fig
pa
share
sequenc
similar
ident
pro
level
similar
one
highest
found
chymotrypsinlik
proteas
analys
data
shown
sequenc
similar
pa
pro
rais
hypothesi
pi
molecul
might
bind
pa
similarli
pro
although
substitut
put
catalyt
ser
residu
proteas
activ
pa
differ
report
affect
viral
replic
fodor
et
al
toyoda
et
al
log
reduct
viral
replic
mice
intranas
infect
viru
express
ser
ala
pa
mutant
lack
proteas
activ
pfu
mutant
virusinfect
mice
versu
pfu
control
observ
toyoda
et
al
suggest
protein
merit
attent
target
pharmacolog
intervent
similar
mutant
construct
fodor
et
al
previou
studi
display
reduc
replic
capac
cell
cultur
differ
result
like
attribut
fact
toyoda
et
al
conduct
test
mous
model
wherea
fodor
cowork
monitor
viral
replic
cell
line
model
cell
line
may
deviat
vivo
condit
number
molecular
characterist
differ
result
vitro
vivo
model
reminisc
result
sarscov
pro
inhibit
describ
previou
section
paper
reflect
need
research
moreov
fodor
et
al
report
paper
ala
substitut
pa
produc
replicationdefect
virus
note
put
catalyt
residu
possibl
chymotrypsin
activ
author
attribut
observ
impair
capac
mutat
rdrp
transcrib
viral
rna
vrna
mrna
defect
endonucleolyt
activ
requir
exert
function
inde
three
rdrp
subunit
pa
requir
effici
synthesi
rna
transcript
interact
pa
low
resolut
structur
model
influenza
ribonucleoprotein
particl
gener
electron
microscopi
suggest
rather
compact
structur
polymeras
complex
et
al
observ
toyoda
fodor
necessarili
mutual
exclus
inde
seem
directli
involv
endonucleolyt
reaction
fodor
et
al
event
reduct
viral
replic
observ
vivo
toyoda
cowork
becom
achiev
human
treat
pa
inhibitor
might
contribut
attenu
lifethreaten
manifest
avian
influenza
altern
pa
inhibitor
might
use
combin
strategi
order
impair
viral
life
cycl
multipl
step
structur
rdrp
crystallograph
solv
yet
studi
necessari
develop
specif
inhibitor
avail
xray
structur
pa
like
take
long
time
model
chymotrypsinlik
compon
pa
chicken
influenza
viru
isol
ncbi
access
number
base
xray
solv
structur
bovin
protein
data
bank
access
number
although
usual
difficult
predict
protein
fold
base
structur
homologu
less
sequenc
ident
approach
homolog
model
valid
case
experiment
observ
show
chymotrypsinlik
proteas
show
extrem
conserv
fold
even
homolog
primari
structur
quit
low
architectur
sarscov
pro
describ
fig
constitut
exampl
despit
chymotrypsin
structur
pro
share
sequenc
ident
fig
lower
share
pa
extrem
conserv
fold
probabl
forc
evolut
order
maintain
activ
chymotrypsinlik
enzym
moreov
worth
note
pa
sequenc
may
vari
lot
even
among
influenza
virus
howev
accord
estim
level
sequenc
similar
result
similar
independ
viral
variant
analys
data
shown
sinc
abovement
research
fodor
et
al
tayada
cowork
suggest
carboxytermin
region
pa
play
role
viral
replic
expect
maintain
conserv
architectur
therefor
possibl
hypothesis
posit
allow
mutat
posit
least
compat
kind
mutat
type
mutat
allow
often
depend
mutat
occur
posit
complex
matter
resolv
simpl
sequenc
align
specif
algorithm
necessari
clarifi
point
could
interest
aim
futur
research
comput
simul
dock
three
wellknown
pi
ritonavir
saquinavir
indinavir
pa
indic
ritonavir
compound
highest
gold
fit
score
ie
slightli
higher
obtain
sarscov
pro
estim
correspond
k
well
within
steadyst
concentr
reachabl
vivo
dosag
use
treatment
similar
result
obtain
evalu
dock
ritonavir
pa
structur
calcul
softwar
rosetta
predict
structur
ab
initio
base
protein
sequenc
http
wwwbioinforpi
fig
show
theoret
dock
ritonavir
insid
bind
caviti
pa
accord
model
signific
hydrogen
bond
might
occur
put
catalyt
ser
therefor
review
observ
toyoda
et
al
fodor
et
al
correct
possibl
specul
pi
might
inhibit
either
proteolyt
endonucleolyt
function
pa
fig
theoret
dock
proteas
inhibitor
ritonavir
activ
site
chymotrypsinlik
proteas
domain
pa
subunit
rnadepend
rna
polymeras
avian
influenza
viru
threedimension
structur
coohtermin
portion
pa
obtain
homolog
molecular
model
use
softwar
tool
swiss
model
avail
wwwexpasyorg
model
adjust
manual
match
distanc
catalyt
amino
acid
determin
xray
bovin
protein
data
bank
access
number
molecular
surfac
correspond
asp
ser
shown
blue
yellow
violet
respect
molecular
dock
visualis
obtain
describ
caption
fig
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
result
far
obtain
suggest
pi
taken
consider
studi
context
sar
mayb
influenza
includ
avian
influenza
virus
evid
inhibitori
effect
pi
etiolog
agent
diseas
still
preliminari
case
sar
theoret
case
type
influenza
virus
anyway
demonstr
effect
pi
chymotrypsinlik
viral
proteas
might
open
new
avenu
antivir
research
potenti
effect
pi
sar
extens
studi
inhibitori
effect
pi
pro
well
studi
causal
link
inhibit
pro
antivir
effect
necessari
furthermor
literatur
analys
need
standardis
vitro
test
antisar
compound
appar
order
better
compar
result
obtain
independ
group
moreov
studi
evalu
effect
pi
combin
antisar
drug
need
recent
demonstr
synergist
effect
pi
combin
chloroquin
savarino
et
al
synerg
associ
combin
inhibitori
effect
chloroquin
pi
drugextrud
pump
pglycoprotein
multidrug
resist
associ
protein
like
result
increas
drug
concentr
savarino
et
al
chloroquin
emerg
new
promis
antisar
compound
vitro
keyaert
et
al
pichloroquin
combin
test
sarscovinfect
cell
cultur
order
increas
potenti
pharmacolog
combin
avail
altern
pi
might
regard
lead
design
new
anticoronaviru
compound
possibl
antivir
applic
pi
possibl
chymotrypsinlik
natur
carboxytermin
region
pa
subunit
type
influenza
viru
rdrp
properti
share
enzym
known
suscept
pi
well
theoret
possibl
pi
might
success
dock
put
activ
site
constitut
basi
immedi
test
antiretrovir
drug
influenza
virus
vitro
although
time
research
consid
embryon
stage
recent
human
case
avian
influenza
vietnam
cambodia
prompt
scientif
commun
consid
well
possibl
pharmacolog
strategi
combat
diseas
world
health
organ
recent
issu
alert
emerg
possibl
pandem
subtyp
influenza
viru
wwwwhoint
viru
current
caus
larg
epidem
poultri
acquir
abil
transmit
human
may
futur
acquir
abil
spread
direct
interhuman
transmiss
mortal
infect
peopl
high
sinc
januari
mani
million
death
may
expect
case
global
outbreak
reason
pi
prove
effect
virus
vitro
may
immedi
avail
vivo
test
affect
individu
altern
one
avail
group
antivir
present
avail
viz
neuraminidas
inhibitor
meanwhil
import
studi
pa
underestim
research
need
confirm
observ
hara
cowork
chymotrypsinlik
activ
pa
determin
architectur
crystallograph
analysi
defin
role
orthomyxovirida
life
cycl
research
might
disclos
new
target
futur
pharmacolog
intervent
influenza
